Sign in
CompletedPhase 2/3

Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients

Key facts

Who runs it
Mansoura University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
60 people enrolled
Started
1 Jan 2025
Ended
30 Jan 2026
Type of study
Interventional
Treatments tested
  • Boswellia carterii Extract
  • Educationntal program for IBS patie
Record updated
8 May 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Adults diagnosed with irritable bowel syndrome (IBS) according to Rome III and Rome IV criteria Recurrent abdominal pain occurring at least once weekly during the preceding three months Presence of changes in stool frequency, stool form, or defecation associated with abdominal pain Participants reporting bloating as the primary symptom

Who cannot take part

  • Adherence to special diets (low-fat, lactose-free, or gluten-free diets) within the past six months Food allergies such as soy, nuts, or seafood allergies Insulin-dependent diabetes mellitus Celiac disease Inflammatory bowel disease History of major gastrointestinal surgery, including colonic surgery or cholecystectomy Bloody diarrhea, hematochezia, or melena Recent antibiotic use Presence of alarming gastrointestinal symptoms Severe renal disease Severe hepatic disease Pregnancy Breastfeeding

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Irritable bowel syndrome (IBS) is a common condition that affects the stomach and intestines. It can cause abdominal pain, bloating, diarrhea, constipation, and changes in bowel habits, which may reduce a person's quality of life. Many people with IBS do not achieve complete symptom relief with standard treatments.

Read full original descriptionShow less

The purpose of this study is to evaluate whether a standardized Boswellia extract, combined with structured patient education, can help improve IBS symptoms and quality of life. Boswellia is a herbal extract that may help reduce inflammation and digestive discomfort.

In this study, 60 adults aged 18-39 years with moderate IBS were enrolled at Mansoura University Hospitals, Egypt. Participants received 500 mg of standardized Boswellia extract twice daily for 30 days and attended educational sessions about IBS self-management, including symptom control and healthy lifestyle practices.

Researchers evaluated abdominal pain, bloating, bowel habits, other gastrointestinal symptoms, and quality of life at the start of the study, after one week, and after one month to determine whether the intervention improved IBS symptoms and daily functioning.

The group in the trial

  • Participants received 500 mg standardized Boswellia extract (≥65% boswellic acids) twice dailyTreatment being tested

    Phytochemical standardization of the Boswellia carterii oleogum resin extract was conducted at the FAB-Lab (Faculty of Pharmacy, Mansoura University) to ensure batch-to-batch consistency and defined bioactive content. The extract was standardized to contain ≥65% total boswellic acids, based on previously established analytical and isolation methodologies developed in our laboratory. These procedures include chromatographic separation and characterization of immunomodulatory triterpenoids(7), as well as validation of leukotriene-inhibitory activity and bioactive compound profiling, as described in earlier pharmacological and clinical investigations of Boswellia preparations(8). The standardization approach has been consistently applied in prior experimental and clinical studies evaluating anti-inflammatory, immunomodulatory, antiviral, and osteoarthritis-related therapeutic effects of Boswellia-derived compounds, thereby ensuring reproducibility, phytochemical integrity, and biological

    Treatment: Boswellia carterii Extract and Educationntal program for IBS patie

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Quasi-experimental Study Evaluating a Standardized Boswellia Carterii Extract Combined With Structured Patient Education in IBS
Record updated
8 May 2026